The bisphosphonate zoledronate prevents vertebral bone loss in mature estrogen-deficient rats as assessed by micro-computed tomography.

@article{Glatt2001TheBZ,
  title={The bisphosphonate zoledronate prevents vertebral bone loss in mature estrogen-deficient rats as assessed by micro-computed tomography.},
  author={Markus Glatt},
  journal={European cells & materials},
  year={2001},
  volume={1},
  pages={
          18-26
        }
}
The effect of long-term treatment with the bisphosphonate zoledronate on vertebral bone architecture was investigated in estrogen-deficient mature rats. 4-month-old rats were ovariectomized and development of cancellous osteopenia was assessed after 1 year. The change of bone architectural parameters was determined with a microtomographic instrument of high resolution. After 1 year of estrogen-deficiency, animals lost 55% of vertebral trabecular bone in comparison to sham operated control… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 46 REFERENCES

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.

  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1994
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

pattern factor – a new parameter for simple quantification of bone microarchitecture

MA Haidekker, R Andresen, HJ Werner
  • 1999
VIEW 1 EXCERPT

Acute changes in trabecular bone connectivity and osteoclast activity in the ovariectomized rat in vivo.

  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1998

Similar Papers